National Academies Press: OpenBook
« Previous: Appendix E: Model Federal Programs in Pharmaceutical R&D
Suggested Citation:"Appendix F: Workshop Agenda and Participants." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 238
Suggested Citation:"Appendix F: Workshop Agenda and Participants." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 239
Suggested Citation:"Appendix F: Workshop Agenda and Participants." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 240
Suggested Citation:"Appendix F: Workshop Agenda and Participants." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 241

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix F Workshop Agenda and Participants Institute of Medicine Committee to Study Medication Development and Research at the National Institute on Drug Abuse Workshop on Policies to Stimulate Private Sector Development of Anti-Addiction Medications June 13, 1994 Lecture Room, National Academy of Sciences 2101 Constitution Avenue, N.W. Washington, D.C. WORKSHOP AGENDA 8:00~:30 a.m. BREAKFAST 8:30 8:45 OPENING REMARKS Laurence E. Earley, Chairman 8:4~10:45 Panel I: Private Sector Obstacles and Opportunities Moderator: J. Richard Crout Panel: Dee Gillespie, Steve Grossman, Richard Merrill, Sherri Samotin* 10:4~12:30 Panel II: Regulatory Issues Moderator: Herbert Kleber Panel: Robert Angarola, John Coleman, George DeVaux*, Nicholas Reuter, Frank Vocci 238

APPENDIX F 12:30-1 :15 LUNCH 1:15-2:30 Panel III: Research and Training Issues Moderator: Kathleen Foley Panel: John Ambre, Ann Geller, Charles Grudzinskas, David Lewis* 2:30-4:00 Panel IV: Treatment Financing Issues Moderator: Peter Carpenter Panel: John Caulkins*, Jack Durell*, Eric Goplerud 4:0~5:00 Plenary Session 5:00 * Presenters 239 Adjourn

240 DEVELOPMENT OF MEDICATIONS PARTICIPANT LIST John Ambre American Medical Association Robert Angarola Hyman, Phelps and McNamara Gary Bennett National Institute of Dental Research Ann Carter Drug Enforcement Administration John Caulkins RAND John Coleman Drug Enforcement Administration Leonard Cook National Institute on Drug Abuse James Cooper National Institute on Drug Abuse Paul Coulis National Institute on Drug Abuse Miriam Davis Health Policy Consultant George DeVaux BioDevelopment Corporation Chris Doherty Fox, Bennett and Turner Jack Durell Treatment Research Institute Joel Egertson National Institute on Drug Abuse John Engel Fox, Bennett and Turner Susan Everingham RAND Lorraine Fishback Department of Health and Human Services Gretchen Freshneur Drug Enforcement Administration Jim Friedman Substance Abuse and Mental Health Services Administration Ann Geller American Society of Addiction Medicine Dee Gillespie DuPont-Merck Steve Grossman Hill and Knowlton Charles Grudzinskas National Institute on Drug Abuse Anthony Guarino University of South Alabama

APPENDIX F Thomas Hefffier Parke-Davis Pharmaceutical Research James Isbister Pharmavene, Inc. Jerome Jaffe Substance Abuse and Mental Health Services Administration Betty Jones Food and Drug Administration Thomas Kuchenberg Food and Drug Administration Irwin Lerner Hoffman-LaRoche David Lewis Brown University Barbara McGarey National Institutes of Health Richard Merrill University of Virginia School of Law Jacques Normand National Research Council Marcy Oppenheimer Department of Health and Human Services 241 Richard Rettig Institute of Medicine Nicholas Reuter Food and Drug Administration Barbara Roberts Office of National Drug Control Policy Sherri Samotin Wilkerson Group, Inc. Frank Sapienza Drug Enforcement Administration Robert Talbot-Stern Legal Consultant John Thomas BioDevelopment Corporation Frank Vocci National Institute on Drug Abuse Bonnie Wilford George Washington University Curtis Wright Food and Drug Administration Thomas Wyatt National Association of State Controlled Substance Authorities

Next: Appendix G: Health Care Reform Legislation »
The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector Get This Book
×
Buy Paperback | $54.00 Buy Ebook | $43.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!